2014
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. Journal Of Clinical Oncology 2014, 32: 3483-3489. PMID: 24888818, PMCID: PMC4209100, DOI: 10.1200/jco.2014.56.2561.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerFirst-line chemotherapyMedian overall survivalDays of therapyOverall survivalInitial therapyBreast cancerTumor cellsTrial of patientsMore effective treatmentsEvaluable patientsStandard chemotherapyPrimary outcomeArm APoor prognosisPrognostic significanceCytotoxic therapyAlternative chemotherapyEffective treatmentChemotherapyPatientsTherapyEarly switchingPersistent increaseMonthsDuration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study
Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and Toxicity of Adjuvant Trastuzumab in Older Patients With Early-Stage Breast Cancer: A Population-Based Study. Journal Of Clinical Oncology 2014, 32: 927-934. PMID: 24516021, PMCID: PMC3948095, DOI: 10.1200/jco.2013.51.1261.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerCardiac eventsOlder patientsBreast cancerTrastuzumab completionAdjuvant trastuzumabTreatment completionOlder womenHuman epidermal growth factor receptorAdjuvant trastuzumab useAge 76 yearsDays of therapyMost older patientsSignificant cardiac eventsMultivariable logistic regressionEpidermal growth factor receptorGrowth factor receptorMore comorbiditiesTrastuzumab useComorbidity scorePatient ageHospital admissionOptimal treatmentLower oddsMedicare data
2013
Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC).
Freedman R, Luis I, Lin N, Lii J, Winer E, Keating N. Completion of adjuvant trastuzumab for older patients with early-stage breast cancer (BC). Journal Of Clinical Oncology 2013, 31: 616-616. DOI: 10.1200/jco.2013.31.15_suppl.616.Peer-Reviewed Original ResearchEarly-stage breast cancerBreast cancerAdjuvant trastuzumabCardiac eventsOlder womenTrastuzumab completionOlder patientsHospital admissionDays of therapyTaxane-based therapyMultivariable logistic regressionMore comorbiditiesLower oddsHispanic womenMedicare dataTrastuzumabPatientsTherapyLogistic regressionWomenComorbiditiesChemotherapyAdmissionOne-quarterTreatment
2012
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. Journal Of Clinical Oncology 2012, 30: 2615-2623. PMID: 22665533, PMCID: PMC3413275, DOI: 10.1200/jco.2010.34.5579.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCarboplatinCetuximabDisease ProgressionFemaleHumansMiddle AgedNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSignal TransductionSurvival AnalysisTreatment OutcomeConceptsTriple-negative breast cancerMetastatic triple-negative breast cancerOverall survivalResponse rateBreast cancerEpidermal growth factor receptorMost triple-negative breast cancersRandomized phase II trialBasal-like molecular subtypeBasal-like breast cancerEGFR pathwayArchival tissuePhase II studyPrimary end pointDays of therapyPhase II trialStrong preclinical dataEGFR antibody cetuximabFresh tumor tissueCombination cetuximabConcomitant therapyGrowth factor receptorCarboplatin regimenDisease stabilizationII trial